Hennion & Walsh Asset Management, Inc. Altimmune, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 188,955 shares of ALT stock, worth $752,040. This represents 0.03% of its overall portfolio holdings.
Number of Shares
188,955
Previous 197,684
4.42%
Holding current value
$752,040
Previous $1.05 Million
30.45%
% of portfolio
0.03%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding ALT
# of Institutions
217Shares Held
36.3MCall Options Held
4.92MPut Options Held
4.18M-
Black Rock Inc. New York, NY5.32MShares$21.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$20.6 Million0.0% of portfolio
-
State Street Corp Boston, MA2.75MShares$11 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$10.9 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$7.7 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $195M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...